This paper is in the following e-collection/theme issue:

Non-Randomized Studies (funded, non-eHealth) (143) Anxiety and Stress Disorders (1053) Depression and Mood Disorders; Suicide Prevention (1363)

Published on in Vol 9, No 6 (2020): June

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/17223, first published .
The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression and/or Generalized Anxiety Disorder: Protocol for a Phase 1, Open-Label Study

The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression and/or Generalized Anxiety Disorder: Protocol for a Phase 1, Open-Label Study

The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression and/or Generalized Anxiety Disorder: Protocol for a Phase 1, Open-Label Study

Authors of this article:

Arthi Chinna Meyyappan1, 2, 3 Author Orcid Image ;   Roumen Milev1, 2, 3, 4 Author Orcid Image
Article Authors Cited by (10) Tweetations (8) Metrics

Journals

  1. Chinna Meyyappan A, Forth E, Wallace C, Milev R. Effect of fecal microbiota transplant on symptoms of psychiatric disorders: a systematic review. BMC Psychiatry 2020;20(1) View
  2. Martins L, Braga Tibães J, Sanches M, Jacka F, Berk M, Teixeira A. Nutrition-based interventions for mood disorders. Expert Review of Neurotherapeutics 2021;21(3):303 View
  3. Chinna Meyyappan A, Sgarbossa C, Vazquez G, Bond D, Müller D, Milev R. The Safety and Efficacy of Microbial Ecosystem Therapeutic-2 in People With Major Depression: Protocol for a Phase 2, Double-Blind, Placebo-Controlled Study. JMIR Research Protocols 2021;10(9):e31439 View
  4. Chunduri A, Reddy S, Jahanavi M, Reddy C. Gut–Brain Axis, Neurodegeneration and Mental Health: A Personalized Medicine Perspective. Indian Journal of Microbiology 2022;62(4):505 View
  5. Kumar D, Ashraf G, Hassan M. Therapeutic Integrity of Microbiome-based Medicines in Neurodegenerative Disorders. Current Neuropharmacology 2022;20(11):2014 View
  6. Chinna Meyyappan A, Forth E, Milev R. Microbial Ecosystem Therapeutic-2 Intervention in People With Major Depressive Disorder and Generalized Anxiety Disorder: Phase 1, Open-Label Study. Interactive Journal of Medical Research 2022;11(1):e32234 View
  7. Li S, Zhang Y. Sensitive delivery systems and novel encapsulation technologies for live biotherapeutic products and probiotics. Critical Reviews in Microbiology 2024;50(3):371 View
  8. Li Q, Ma Z, Qin S, Zhao W. Virtual Screening-Based Drug Development for the Treatment of Nervous System Diseases. Current Neuropharmacology 2023;21(12):2447 View
  9. Vashishth S, Ambasta R, Kumar P. Deciphering the microbial map and its implications in the therapeutics of neurodegenerative disorder. Ageing Research Reviews 2024;100:102466 View
  10. Bahmani M, Mehrtabar S, Jafarizadeh A, Zoghi S, Heravi F, Abbasi A, Sanaie S, Rahnemayan S, Leylabadlo H. The Gut Microbiota and Major Depressive Disorder: Current Understanding and Novel Therapeutic Strategies. Current Pharmaceutical Biotechnology 2024;25(16):2089 View